Prognostic importance of the time interval from surgery to chemotherapy in treatment of ovarian carcinoma

被引:19
作者
Sorbe, B [1 ]
机构
[1] Orebro Univ Hosp, Dept Gynecol Oncol, SE-70185 Orebro, Sweden
关键词
chemotherapy; ovarian carcinoma; prognostic factors; surgery; time factor;
D O I
10.1111/j.1048-891X.2004.014509.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a large study on 1220 patients with ovarian carcinoma in FIGO stages I-IV, the prognostic importance of the time factor for start of postoperative chemotherapy was studied together with other important factors for long-term survival. The patient series was a total geographic material of ovarian carcinoma patients treated during the years 1975-1993. All patients were followed up for 10 years or until death. The 5-year cancer-specific survival rate of the complete series was 50%. Significant and independent prognostic factors with regard to long-term cancer-specific survival were FIGO stage, histology, tumor grade, and completeness of the primary surgery. Special attention was paid to the prognostic importance of the time interval between primary surgery and the first course of chemotherapy. Patient groups with intervals shorter or longer than the median value were compared. In early-stage disease, no significant difference was noted. In advanced and bulky disease, an interval longer than the median value seemed to be beneficial compared with a shorter interval. However, after correction for other prognostic factors, the interval was not a significant factor (P = 0.647) with regard to the cancer-specific survival rate. Therefore, the time factor should not be an important argument for how to best organize the gynecologic oncology service.
引用
收藏
页码:788 / 793
页数:6
相关论文
共 13 条
[1]   Why do ovarian cancer patients not consult a gynecologic oncologist? Reply [J].
Carney, ME .
GYNECOLOGIC ONCOLOGY, 2002, 87 (01) :158-158
[2]  
COX DR, 1972, J R STAT SOC B, V34, P187
[3]   Outcomes in surgery for ovarian cancer [J].
Elit, L ;
Bondy, SJ ;
Paszat, L ;
Przybysz, R ;
Levine, M .
GYNECOLOGIC ONCOLOGY, 2002, 87 (03) :260-267
[4]   Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? [J].
Flynn, PM ;
Paul, J ;
Cruickshank, DJ .
GYNECOLOGIC ONCOLOGY, 2002, 86 (03) :354-357
[5]   Survival of European women with gynaecological tumours, during the period 1978-1989 [J].
Gatta, G ;
Lasota, MB ;
Verdecchia, A .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (14) :2218-2225
[6]  
Hogberg T, 1997, Lakartidningen, V94, P28
[7]   Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients [J].
Junor, EJ ;
Hole, DJ ;
McNulty, L ;
Mason, M ;
Young, J .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (11) :1130-1136
[8]   Evidence of benefit from centralised treatment of ovarian cancer:: A nationwide population-based survival analysis in Finland [J].
Kumpulainen, S ;
Grénman, S ;
Kyyrönen, P ;
Pukkala, E ;
Sankila, R .
INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (05) :541-544
[9]   OVARIAN-CANCER STAGING - DOES IT REQUIRE A GYNECOLOGIC ONCOLOGIST [J].
MAYER, AR ;
CHAMBERS, SK ;
GRAVES, E ;
HOLM, C ;
TSENG, PC ;
NELSON, BE ;
SCHWARTZ, PE .
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :223-227
[10]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6